In a study of front-line providers, the psychedelic drug reduced symptoms of depression more effectively than a placebo. https://newsroom.uw.edu/news-releases/psilocybin-therapy-helps-clinicians-process-covid-despair Psilocybin-assisted psychotherapy resulted in significant reductions in depression among clinicians who provided front-line COVID-19 care in 2020 and 2021. These reductions were measurably greater than those experienced by the cohort of clinicians who received a

Psilocybin leads to a better overall outcome in the treatment of moderate to severe major depressive disorder (MDD) than the selective serotonin reuptake inhibitor (SSRI) escitalopram, results of the first long-term comparison of the two treatments suggest. "This is the first work to compare the long-term effects of these two drugs in the context of overall well-being, not just freedom from depression," study investigator Tommaso Barba, PhD, candidate Imperial College London,

As the wider culture is experiencing what some call a “psychedelic renaissance,” various Christian voices are beginning to comment on this cultural moment in the press and social media. Some are curious, even open minded, about the developments; others are expressing concern about what they see as the inauthenticity and danger of psychedelics as a spiritual practice. Absent, however, is discussion of how a Christian psychedelic practice might look. Click here to read this art

According to CNN, a clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced Thursday. The biopharmaceutical company is developing the drug. “A breakthrough designation is a recognition that a drug has demonstrated evidence of clinical efficacy in meeting an unmet medical need with morbidity and mortality associated with it,” said Dr. Daniel K

Integration is a critical component of the safe and effective use of psychedelics. This process allows us to bring the lessons of our psychedelic experiences into daily life, ensuring we fully learn and grow from what the substances show us. With support from The Primed Foundation, Multidisciplinary Association for Psychedelic Studies (MAPS) created a website and downloadable workbook dedicated to integration techniques to help people process, understand, and incorporate psyc

Source: The Microdose Psychedelics like psilocybin, MDMA, LSD, and DMT act on serotonin receptors, and previous research has found that other drugs that act on serotonin receptors, such as the weight loss drug fen-phen, can cause fibrosis, or the thickening of heart valves. That, in turn, can lead to serious or even fatal heart issues like arrhythmias or valvular heart disease. So far, there’s been little research on the link between repeated psychedelics use and heart health

Psychedelics in Recovery (PIR) is a fellowship of people in 12-step programs who also have an interest in psychedelics and/or plant medicines as an aid to their recovery. After six years of deeply strategic, thoughtful, and deliberate peer-led self-organizing, the recovery fellowship known as PIR has registered as a nonprofit corporation in the state of Colorado. You can read more on the PIR website and in this Q&A in the Community Psychologist. At Oasis Wellness & Recovery,

Grinspoon discusses recovery, addiction and whether psychedelics might have a role in addiction treatment. Traditionally, recovery has been looked at as the absence of drugs. Maybe we are thinking about it the wrong way? At Mass General, they have multidisciplinary teams — a primary care doctor who understands addiction and prescribes medications like Suboxone; an addiction psychiatrist; a recovery coach to provide individual peer support; social workers to help people with h

MDMA-assisted psychotherapy proved safe and effective in treating post-traumatic stress disorder (PTSD) symptoms in a diverse patient population, according to findings from the phase III randomized MAPP2 trial (Nature Medicine). Sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), the study included around 100 participants, roughly half were given MDMA, while the other half received a placebo. By the end of the study, 71% of those who received MDMA-a

Writer and Baby Boomer Abbie Rosner shares her knowledge on the death-positive movement and creating new end-of-life rituals with the help of psychedelics. Read more here.

Kids soak up new skills, adults not so much. But neuroscientist Gül Dölen might have found a way to help grown-ups learn like kids. Read this fascinating Wired article that reviews years of research suggesting that psychedelics (including ketamine) are a "reset button” for the mind, reopening critical learning periods and restoring social reward learning.

Recently, psychedelic research has been investigating the effects of psychedelic therapy on treating eating disorders (ED). Specifically, four psychedelic substances have shown promising results: Ayahuasca, Ketamine, MDMA, and Psilocybin. Read on to find out about the latest research on these psychedelics and their potential for treating EDs. Find out about Ketamine-Assisted Psychotherapy at Oasis Wellness & Recovery

Have you felt stuck in negative thought patterns? Are you spiraling into self-criticism from unresolved pain from the past? Albert Einstein once said, “We can’t solve problems by using the same kind of thinking we used when we created them.” Psychedelic Assisted Therapy can help you see more options, open neuro pathways, and enter a fresh perspective of thinking and feeling. You can find your answers. Join me and many others on the journey to new insights and awareness.

Psilocybin, MDMA, and ketamine can lead to a new sense of self and a release from rigid rules for people with anorexia, bulimia, and binge-eating disorder. Find out more in this insightful article on Proto.Life.

According to NBC news, schools are ramping up training programs to teach therapists and other practitioners how to safely give psychedelics to patients. Our providers, Dr. Eric Milbrandt and Gay Lynn Williamson-Grigas, are graduates of two prestigious programs (CIIS and MAPS), and are already providing psychedelic assisted therapy with ketamine. We will begin offering psilocybin and MDMA as soon as it is FDA approved, which could be as early as 2024!

A combination of psychedelics and therapy appears to help people with alcoholism cut down on the number of days per month they drink heavily, according to a new study. Researchers used psilocybin, the psychedelic compound found in magic mushrooms, to treat patients over eight months and saw a dramatic improvement in participants’ drinking habits. While we await legal access to psilocybin, we at The Infusion Clinic of Ocala are getting similar results with IV ketamine therapy.

Excited to announce my recent certification in Psychedelic-Assisted Therapies and Research from CIIS (California Institute of Integral Studies). Psychedelic-assisted therapies offer real hope to those suffering from treatment-resistant depression, anxiety, and PTSD!

Inside the growing—and, to some, controversial—movement in which parents are using psychedelics to take the edge off modern parenthood. - Harpers Bazaar 2022 At the Infusion Clinic of Ocala, we plan to offer psilocybin-assisted therapy as soon as we can legally do so. Dr. Milbrandt is CIIS and MAPS trained to provide this transformative treatment. While you wait, check out our ketamine-assisted therapy option.

A new study shows that MDMA, known as Ecstasy or Molly, can bring relief when paired with talk therapy to those with severe post-traumatic stress disorder. In today's edition of The New York Times newspaper on page A12, the world-renowned publication reveals research results from the first Phase 3 clinical trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD). "In an important step toward medical approval, MDMA . . . was shown to bring relief to those suffer

The center, believed to be the first and largest of its kind, will use psychedelics to study the mind and identify therapies for diseases such as addiction, PTSD, and Alzheimer's. https://hub.jhu.edu/2019/09/04/hopkins-launches-psychedelic-center/ Note from Dr. Milbrandt - I will be training next year to offer these therapies once the FDA opens up expanded access research programs. It probably won't happen until 2021 but exciting none-the-less!